Press Center

Today, Orient EuroPharma (4120) and Second Sight Medical Products signed a cooperation agreement to obtain the exclusive distribution rights for the Argus II Retinal Prosthesis System in Taiwan. The Argus II represents a breakthrough implantable bionic eye technology and will benefit local patients suffering from retinitis pigmentosa.

Retinitis Pigmentosa (RP) is a hereditary eye disease that can lead to the deterioration of eyesight and even blindness. Currently, there is no effective treatment*. The Argus II Retinal Prosthesis System, exclusive technology from the American firm Second Sight Medical Products, works by converting images captured by a miniature video camera mounted on the patient's glasses into a series of small electrical pulses, which are transmitted wirelessly to an array of electrodes implanted on the surface of the retina. These pulses are intended to stimulate the retina's remaining cells, resulting in the perception of patterns of light in the brain. The patient then learns to interpret these visual patterns through proper training, thereby regaining some visual function. Patients can not only enjoy independence but also experience a higher quality of life as their interaction with the outside world improves.

The Argus II was selected as one of the Best Inventions of 2013 by  Time Magazine and was recognized the CNN 10 Inventions of 2013 for its technological advancement and contribution. This year, US President Barack Obama also awarded the co-inventor of the Argus II, Mark Humayun, the National Medal of Technology and Innovation, the highest honor for technological achievement in the United States.

Last year, Orient EuroPharma signed a cooperation agreement for regenerative medical ophthalmology with the American biotech firm TissueTech™. Today, Orient EuroPharma extends its cooperation to Second Sight Medical Product by obtaining the exclusive distribution rights for the Argus II in Taiwan.

*Taiwan orphan disease database: http://www.genes-at-taiwan.com.tw